Polaryx Therapeutics, Inc. Common Stock
NASDAQ Global MarketTotal Valuation
Polaryx Therapeutics, Inc. Common Stock carries a market capitalization of 114.65M, placing it among publicly traded companies globally.
| Market Cap | 114.65M |
| Enterprise Value | N/A |
Share Statistics
Polaryx Therapeutics, Inc. Common Stock currently has 47.34M shares outstanding.
| Shares Outstanding | 47.34M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -3.50 |
| P/TBV Ratio | 143.73 |
| P/FCF Ratio | -67.50 |
| P/OCF Ratio | -67.50 |
Financial Position
Polaryx Therapeutics, Inc. Common Stock maintains a current ratio of 3.45, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.45 |
| Quick Ratio | 3.04 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -163.15 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Polaryx Therapeutics, Inc. Common Stock's stock has declined approximately -93.42857% over the past 52 weeks. The 50-day moving average sits at 2.69, while the 200-day moving average is 4.65.
| Beta (5Y) | N/A |
| 52-Week Price Change | -93.42857% |
| 50-Day Moving Average | 2.69 |
| 200-Day Moving Average | 4.65 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -4.73M, while operating income came in at -4.73M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -4.73M |
| Pretax Income | -6.48M |
| Net Income | -6.48M |
| EBITDA | -4.73M |
| EBIT | -4.73M |
| Earnings Per Share (EPS) | -0.14 |
Balance Sheet
Total book value stands at -102.17M, with working capital of 2.49M providing operational flexibility.
| Cash & Cash Equivalents | 3.08M |
| Total Debt | N/A |
| Net Debt | -3.08M |
| Equity (Book Value) | -102.17M |
| Book Value Per Share | -2.16 |
| Working Capital | 2.49M |
Cash Flow
Polaryx Therapeutics, Inc. Common Stock produced -5.30M in operating cash flow over the past twelve months.
| Operating Cash Flow | -5.30M |
| Capital Expenditures | N/A |
| Free Cash Flow | -5.30M |
| FCF Per Share | -0.11 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -1.18 |
| FCF Yield | -1.48 |
Scores
Polaryx Therapeutics, Inc. Common Stock posts an Altman Z-Score of 167.15, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 167.15 |